Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kajoor Sudhakara

Internal Medicine Trenton, MI Medical Doctor

NPI 1295840734 CMS profile 104430

1675 Kingsway Ct, Trenton, MI 48183

Open in the dashboard

General payments

$11,014

681 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kajoor Sudhakara of Trenton, MI is reported in the CMS Open Payments database as having received $11,014 across 681 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,421 74
2024 General $1,743 95
2023 General $1,782 104
2022 General $1,627 101
2021 General $2,076 125
2020 General $1,279 96
2019 General $1,086 86

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kajoor Sudhakara
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Kajoor Sudhakara were reported at $1,421. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Kajoor Sudhakara Internal Medicine median Middle half National median
2019 $1,086 $159 $48–$570 $163
2020 $1,279 $119 $33–$402 $114
2021 $2,076 $135 $37–$521 $132
2022 $1,627 $141 $42–$496 $149
2023 $1,782 $149 $45–$519 $160
2024 $1,743 $154 $47–$537 $164
2025 $1,421 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,385 105 payments
  2. AbbVie, Inc. $1,196 72 payments
  3. Lilly USA, LLC $1,112 78 payments
  4. GlaxoSmithKline, LLC. $1,043 71 payments
  5. AstraZeneca Pharmaceuticals LP $837 39 payments
  6. Pfizer Inc. $535 32 payments
  7. Janssen Pharmaceuticals, Inc $505 30 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $359 21 payments
  9. Novartis Pharmaceuticals Corporation $350 21 payments
  10. Teva Pharmaceuticals USA, Inc. $240 16 payments
  11. Other $3,453 196 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,948 680 payments
  2. Education $66 1 payment
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $773 50 payments
  2. Ozempic $715 59 payments
  3. RYBELSUS $695 56 payments
  4. VRAYLAR $683 39 payments
  5. TRULICITY $536 39 payments
  6. XARELTO $505 30 payments
  7. JARDIANCE $454 32 payments
  8. XIFAXAN $359 21 payments
  9. NURTEC ODT $347 20 payments
  10. ENTRESTO $335 20 payments
  11. Other $8,029 491 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 91 drugs

Part D claims

3,056

Median for Internal Medicine: 777

Drug cost

$351,482

Median for Internal Medicine: $73,373

Branded share of claims

27.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 57 $56,870
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 52 $39,155
Eliquis Apixaban Brand 39 $33,877
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 27 $26,745
Mounjaro Tirzepatide Brand 24 $26,539
Januvia Sitagliptin Phosphate Brand 29 $24,944
Jardiance Empagliflozin Brand 14 $17,505
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 15 $16,616
Farxiga Dapagliflozin Propanediol Brand 16 $15,018
Tradjenta Linagliptin Brand 13 $14,539

The 10 drugs with the highest cost, of 91 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$44,956

Of which drugs: $23

Medicare patients

132

Average age 76

Services billed

710

67 women, 65 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
COPD 48%
Chronic kidney disease 46%
Ischemic heart disease 45%
Diabetes 39%
Heart failure 39%
Atrial fibrillation 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $214
$214 — —
JARDIANCE
  • Lilly USA, LLC $109
  • Boehringer Ingelheim Pharmaceuticals, Inc. $37
$146 14 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $115
$115 52 —
Wegovy
  • Novo Nordisk Inc $105
$105 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $103
$103 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

681 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record